Maravai LifeSciences Holdings, Inc. (MRVI)

MRVI Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	561.69	574.96	632.14	551.27	236.18	24.7
Cash & Cash Equivalents	561.69	574.96	632.14	551.27	236.18	24.7
Cash Growth	-10.60%	-9.04%	14.67%	133.41%	856.21%	12.96%
Receivables	36.69	54.61	138.62	117.51	51.02	18.03
Inventory	49.85	51.4	43.15	51.56	33.3	14.2
Other Current Assets	19.66	18.95	33.99	19.7	11.1	3.62
Total Current Assets	667.88	699.91	847.9	740.04	331.6	60.55
Property, Plant & Equipment	161.63	162.9	52.69	46.33	101.31	94.31
Goodwill and Intangibles	540.15	547.02	500.33	270.34	401.93	422.13
Other Long-Term Assets	74.98	77.62	881.39	861.57	435.86	0.81
Total Long-Term Assets	776.76	787.54	1,434	1,178	939.09	517.24
Total Assets	1,445	1,487	2,282	1,918	1,271	577.8
Accounts Payable	8.23	10.73	5.99	8.15	8.17	7.48
Deferred Revenue	2.21	3.36	3.09	10.21	78.06	0.84
Current Debt	6.11	6.07	5.44	6	6	2.5
Other Current Liabilities	42.47	67.31	95.63	69.41	38.55	18.74
Total Current Liabilities	59.02	87.47	110.14	93.78	130.78	29.56
Long-Term Debt	549.61	550.6	522	524.59	584.78	387.7
Other Long-Term Liabilities	58.62	59.49	744.93	754.55	400.39	15.91
Total Long-Term Liabilities	608.23	610.1	1,267	1,279	985.17	403.61
Total Liabilities	667.25	697.57	1,377	1,373	1,116	433.17
Total Debt	555.72	556.68	527.44	530.59	590.78	390.2
Debt Growth	2.25%	5.54%	-0.59%	-10.19%	51.40%	14.80%
Retained Earnings	273.66	285.74	404.77	184.56	0.85	-42.38
Comprehensive Income	0	0	0	0	-0.04	-0.13
Shareholders' Equity	410.66	416.75	545.22	315.5	88.51	141.4
Net Cash / Debt	5.97	18.29	104.7	20.68	-354.6	-365.5
Net Cash / Debt Growth	-92.96%	-82.54%	406.27%	-	-	-
Net Cash Per Share	0.05	0.14	0.41	0.08	-12.27	-1.44
Working Capital	608.86	612.44	737.76	646.26	200.82	30.99
Book Value Per Share	3.10	3.16	4.14	2.75	8.55	0.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).